Assessment of Cardiovascular Risk.
Summary of "Assessment of Cardiovascular Risk."
Atherosclerotic cardiovascular disease (CVD) is the most common cause of death worldwide. Usually atherosclerosis is caused by the combined effects of multiple risk factors. For this reason, most guidelines on the prevention of CVD stress the assessment of total CVD risk. The most intensive risk factor modification can then be directed towards the individuals who will derive the greatest benefit. To assist the clinician in calculating the effects of these multiple interacting risk factors, a number of risk estimation systems have been developed. This review address several issues regarding total CVD risk assessment: Why should total CVD risk be assessed? What risk estimation systems are available? How well do these systems estimate risk? What are the advantages and disadvantages of the current systems? What are the current limitations of risk estimation systems and how can they be resolved? What new developments have occurred in CVD risk estimation?
Department of Cardiology, Adelaide Meath Hospital, Tallaght, Dublin, 24, Ireland, email@example.com.
This article was published in the following journal.
Name: Current hypertension reports
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20838940
- DOI: http://dx.doi.org/10.1007/s11906-010-0143-1
"CardioTest (®) " is a tool for cardiovascular risk assessment. The aim of this study was to evaluate if this test used in Swiss pharmacies provides risk stratification and if it had impact on indivi...
Hypertensive disease is a major risk factor for cardiovascular morbidity and mortality. Cardiovascular MRI not only provides a non-invasive method for the assessment of potential secondary causes of h...
The incidence of coronary heart disease in premenopausal women is lower than in men because of their hormonal protection. Angina pectoris occurs in women about 10 years later than in men. However, mor...
Accurate risk assessment of atherosclerotic cardiovascular disease (ASCVD) is essential to effectively balance the risks and benefits of therapy for primary prevention.
1. Assessing the perception of Canadian Primary Care Physicians towards global cardiovascular risk assessment. 2. Correlating physician perceptions to actual practice data, gathere...
The RATCHET study assesses if patient knowledge of estimated cardiovascular risk at current and recommended target blood pressure levels improves compliance in the management of hypertensi...
Cardiovascular diseases remain the main cause of mortality in Canada. While effective interventions are available for reducing the risk of cardiovascular disease,there continue to be gaps ...
The purpose of the study is to evaluate the influence of cardiovascular risk factors, heart failure and cardiovascular drug therapy on erectile function in cardiovascular high-risk patient...
To investigate the contributions of neighborhood environments to the distribution of cardiovascular disease (CVD) risk across different age ranges and racial/ethnic groups, using data from...
Medical and Biotech [MESH] Definitions
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
Multidisciplinary field focusing on prevention of infectious diseases and patient safety during international TRAVEL. Key element of the pretravel physician's visit is a health risk assessment.
The science concerned with the benefit and risk of drugs used in populations and the analysis of the outcomes of drug therapies. Pharmacoepidemiologic data come from both clinical trials and epidemiological studies with emphasis on methods for the detection and evaluation of drug-related adverse effects, assessment of risk vs benefit ratios in drug therapy, patterns of drug utilization, the cost-effectiveness of specific drugs, methodology of postmarketing surveillance, and the relation between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines. (Pharmacoepidemiol Drug Saf 1992;1(1); J Pharmacoepidemiol 1990;1(1))
Reduction of high-risk choices and adoption of low-risk quantity and frequency alternatives.
Systematic identification of a population's needs or the assessment of individuals to determine the proper level of services needed.